Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

RPC Children's Non-Aspirin

CGMP Deviations: Products are being recalled due to an out of specification total aerobic microbial count in a water sample.

Terminated Microbial contamination RIJ Pharmaceutical LLC NDC 53807-129-04 D-0845-2018
Class II · Moderate risk

RPC Senna Syrup

CGMP Deviations: Products are being recalled due to an out of specification total aerobic microbial count in a water sample.

Terminated Microbial contamination RIJ Pharmaceutical LLC D-0844-2018
Class II · Moderate risk

Minivelle (estradiol transdermal system)

Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-6637-1 D-0863-2018
Class II · Moderate risk

Minivelle (estradiol transdermal system)

Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-6610-1 D-0862-2018
Class I · High risk

Ampicillin and Sulbactam for Injection

Presence of Particulate Matter: confirmed customer report of the presence of visible particulate matter believed to be red rubber particles from the manufacturing process of the active ingredients.

Terminated Particulate / foreign matter AuroMedics Pharma LLC NDC 55150-117-20 D-0866-2018
Class II · Moderate risk

Loxapine Capsules

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

Terminated Cross-contamination Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-903-20 D-0823-2018
Class II · Moderate risk

Loxapine Capsules

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

Terminated Cross-contamination Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-902-20 D-0822-2018
Class II · Moderate risk

Docetaxel injection concentrate

Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.

Terminated Wrong potency / content Sanofi-Aventis U.S. LLC NDC 0955-1020-01 D-0804-2018
Class III · Low risk

Riomet (metformin hydrochloride oral solution)

Labeling: Not Elsewhere Classified: Sun Pharma has decided to initiate this recall in response to identified labeling discrepancies in the patient literature.

Terminated Labeling / mix-up Sun Pharmaceutical Industries, Inc. NDC 10631-206-02 D-0818-2018

Recalls by year